The Governing Council has approved the processing of a Framework Agreement that will facilitate the supply of these implantable systems, which use electrical impulses to stimulate affected areas of the body. The agreement will have an initial term of 12 months, extendable for up to three additional years.
These neurostimulators have diverse applications. In neurology, they are used to treat conditions such as Parkinson's disease, Tourette syndrome, and epilepsy, potentially improving patients' quality of life. For instance, their placement on the vagus nerve is associated with improvements in epilepsy cases.
Beyond their neurological uses, the devices can regulate arterial hypertension by stimulating the carotid sinuses. In urology, their indication in the sacral roots focuses on treating non-obstructive urinary incontinence and retention, as well as fecal incontinence.
The implementation of this centralized Framework Agreement by the Madrid Health Service (SERMAS) aims to ensure the continuous availability of these devices in all hospitals. Furthermore, the bulk purchasing through joint procurement will allow for more favorable economic conditions and streamline administrative and management processes.
